Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Common Warts (Verruca Vulgaris) · Common Warts · Human Papilloma Virus (HPV) · Warts
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 250 (planned)
- Started
- Mar 11, 2026
- Main results expected
- Nov 2027
- Fully finished
- Nov 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence and severity of AEs including LSRs.
Measured over: Day of transition to this LTFU study to End of Study Visit Day 378.
Change from baseline in vital signs (body temperature)
Measured over: Day of transition to this LTFU study to End of Study Visit Day 378.
Change from baseline in vital signs (pulse)
Measured over: Day of transition to this LTFU study to End of Study Visit Day 378.
Concomitant medication use
Measured over: Day of transition to this LTFU study to End of Study Visit Day 378.
Proportion of subjects achieving clearance (reduction to zero) at the Day 378 EOS Visit of all treatable warts present at Baseline*
Measured over: Baseline* to End of Study Visit Day 378.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07457918 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC